Nautilus Biotechnology Highlights Q4 Progress, Outlines 2026 Plans

Proteomics company reports continued development of its single-molecule analysis platform, with early access program launch and expanded collaborations.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Nautilus Biotechnology used its Q4 2025 earnings call to detail progress on commercializing its proteomics platform, including the launch of an early access program, expanded collaborations, and plans to begin instrument placements and a commercial launch in late 2026. The company also reported cost reductions and updated 2026 spending and revenue expectations.

Why it matters

Nautilus' proprietary 'Iterative Mapping' technology aims to provide high-resolution, single-molecule protein analysis, which could accelerate drug discovery and biomarker research across pharmaceutical, biotech, and academic sectors. The company's progress in product development, partnerships, and commercialization plans signal its platform is nearing market readiness.

The details

Nautilus launched its Iterative Mapping Early Access Program in January 2026, earlier than previously communicated, to support biological discovery, publications, and grant applications while ensuring workflows meet customer needs. The company also highlighted collaborations with the Buck Institute and Allen Institute for Brain Science that have yielded novel insights into tau biology and proteoform patterns. Nautilus plans to expand its proteoform assay portfolio beyond tau, with a focus on oncology targets, and introduce broad-scale capabilities into early access later in 2026. The company expects to begin placing Voyager instruments externally through beta deployments ahead of a commercial launch in late 2026, with general availability of the Voyager platform, tau proteoform assay, and a second proteoform assay.

  • Nautilus launched its Iterative Mapping Early Access Program in January 2026.
  • Nautilus expects to initiate its commercial launch in late 2026 by opening the Voyager platform for pre-orders, with instrument installations beginning in early 2027.

The players

Nautilus Biotechnology

A life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis.

Sujal Patel

Co-founder and CEO of Nautilus Biotechnology.

Parag Mallick

Co-founder and Chief Scientist of Nautilus Biotechnology.

Anna Mowry

Chief Financial Officer of Nautilus Biotechnology.

Buck Institute for Research on Aging

A research institute that collaborated with Nautilus on tau biology research.

Allen Institute for Brain Science

A research institute that collaborated with Nautilus on analyzing human brain samples.

Weill Cornell Medicine-Qatar

A medical school that collaborated with Nautilus on a Parkinson's disease research project funded by the Michael J. Fox Foundation.

Michael J. Fox Foundation (MJFF)

A non-profit organization that is funding a Nautilus collaboration on Parkinson's disease research.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

Nautilus expects to place Voyager instruments externally through beta deployments ahead of its commercial launch in late 2026.

The takeaway

Nautilus' progress in product development, partnerships, and commercialization plans signals its proteomics platform is nearing market readiness, with the potential to accelerate drug discovery and biomarker research across multiple industries.